CSPC Group (01093): Potent aldosterone synthase inhibitors (SYH2072 tablets) approved for clinical trials in China

Zhitong Finance App News, Shiyao Group (01093) issued an announcement. The Class 1 new chemical potent aldosterone synthase inhibitor (SYH2072 tablets) developed by the Group has been approved by the State Drug Administration of the People's Republic of China and can conduct clinical trials in China.

This product is a highly selective and potent aldosterone synthase inhibitor (ASI), which can effectively reduce plasma aldosterone levels without affecting cortisol levels. The clinical indications approved this time are uncontrolled hypertension and primary hyperaldosteronism. Preclinical studies have shown that the product selectively inhibits aldosterone synthase activity, significantly reduces plasma aldosterone levels in animal disease models, and dose-dependently lowers blood pressure in hypertensive models without affecting cortisol levels. The product has good pharmacokinetic (PK) properties and safety, making it a best-in-class (best-in-class) drug. At present, the group has submitted a number of patent applications for this product at home and abroad.

In view of the broad clinical demand for aldosterone synthase inhibitors, this product has high clinical development value and is expected to provide new treatment options for patients with uncontrolled hypertension and primary hyperaldosteronism.